EGFR and non-small cell lung carcinoma: This indication was further expanded in 2020 to include first-line monotherapy for metastatic NSCLC patients with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK alterations [20].